From the Editor’s desk...
EASL LiverTree™, Journal of Hepatology, 203744
In Memoriam: Rudolf Preisig (1929–2017), a major contributor to international hepatology
EASL LiverTree™, Journal of Hepatology, 203745
In Memoriam: Professor Jürg Reichen (1946–2017)
EASL LiverTree™, Journal of Hepatology, 203746
Sequencing of transporter genes in cholestasis: We are still learning
EASL LiverTree™, Journal of Hepatology, 203747
Back to Byzance: Querelles byzantines over NASH and fibrosis
EASL LiverTree™, Journal of Hepatology, 203748
A fatty liver leads to decreased kidney function?
EASL LiverTree™, Journal of Hepatology, 203749
Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s
EASL LiverTree™, Journal of Hepatology, 203750
Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56 NK cells
EASL LiverTree™, Journal of Hepatology, 203751
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients
EASL LiverTree™, Journal of Hepatology, 203752
Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation
EASL LiverTree™, Journal of Hepatology, 203753
Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis
EASL LiverTree™, Journal of Hepatology, 203754
Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015
EASL LiverTree™, Journal of Hepatology, 203755
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
EASL LiverTree™, Journal of Hepatology, 203756
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
EASL LiverTree™, Journal of Hepatology, 203757
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology
EASL LiverTree™, Journal of Hepatology, 203758
Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma
EASL LiverTree™, Journal of Hepatology, 203759
Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury
EASL LiverTree™, Journal of Hepatology, 203760
Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans
EASL LiverTree™, Journal of Hepatology, 203761
Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants
EASL LiverTree™, Journal of Hepatology, 203762
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
EASL LiverTree™, Journal of Hepatology, 203763
Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study
EASL LiverTree™, Journal of Hepatology, 203764
How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?
EASL LiverTree™, Journal of Hepatology, 203765
Primary sclerosing cholangitis – a comprehensive review
EASL LiverTree™, Journal of Hepatology, 203766
Acetaminophen (APAP) hepatotoxicity—Isn’t it time for APAP to go away?
EASL LiverTree™, Journal of Hepatology, 203767
Changes in hemostasis in liver disease
EASL LiverTree™, Journal of Hepatology, 203768
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder
EASL LiverTree™, Journal of Hepatology, 203769
“Empirical” retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen
EASL LiverTree™, Journal of Hepatology, 203770
Non selective beta blockers in cirrhosis
EASL LiverTree™, Journal of Hepatology, 203771
Reply to: “Non selective beta blockers in cirrhosis”
EASL LiverTree™, Journal of Hepatology, 203772
Is room temperature susceptometer really an accurate method to assess hepatocellular iron?
EASL LiverTree™, Anita Paisant, 203773
Reply to: “Is room temperature susceptometry really an accurate method to assess hepatocellular iron?”
EASL LiverTree™, Journal of Hepatology, 203774
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
EASL LiverTree™, John McLauchlan, 203775
Reply to: “Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries”
EASL LiverTree™, Journal of Hepatology, 203776
Performance status in patients with HCC: New kid on the block
EASL LiverTree™, Journal of Hepatology, 203777
Reply to: “Performance status in patients with HCC: New kid on the block”
EASL LiverTree™, Journal of Hepatology, 203778
Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence
EASL LiverTree™, Journal of Hepatology, 203779
Reply to: “Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence”
EASL LiverTree™, Journal of Hepatology, 203780
Addendum to “MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation” [J Hepatol 2013;59:1231–1238]
EASL LiverTree™, Journal of Hepatology, 203781
Concluding remarks
EASL LiverTree™, Session Speakers, 203578
What is needed for drug approval? (Regulatory readouts from fibrosis studies)
EASL LiverTree™, Arun Sanyal, 201634
LOXL2: Lessons learned from the simtuzumab trials
EASL LiverTree™, Robert Myers, 201633
How to non-invasively assess fibrosis (serum, transient elastography, MRE)
EASL LiverTree™, Laurent Castera, 201631
Fibrosis as prognostically relevant signature: - do we have to care about differentiating NASH from NAFL (or just fibrosis)
EASL LiverTree™, Matias Ekstedt, 201630
Randomized Placebo-Controlled Single Blind Clinical Trail: The hepatoprotective effect’s result of new lonal drug in patient with non alcoholic fatty liver disease
EASL LiverTree™, SARNAI Tsagaankhuu, 201561
The Dual Amylin and Calcitonin Receptor Agonist, KBP-089, Improves Metabolic and Hepatic Features of Nonalcoholic Steatohepatitis in High Fat, High Cholesterol Fed Rats
EASL LiverTree™, Sofie Gydesen, 201562
Serum bile acids and fibroblast growth factor 19 levels are associated with fibrosis and hepatic inflammation in hepatocellular cancer based on NASH
EASL LiverTree™, Lars Bechmann, 201564
Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the non-alcoholic steatohepatitis patients
EASL LiverTree™, Tatiana Ermolova, 201565
Anti-oxidant role in reversing Non-Alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma (HCC)
EASL LiverTree™, Valentina Leone, 201566
Fatty liver is associated with increased visceral and cardiac fat and cardiometabolic risk
EASL LiverTree™, Veronica DELLA LATTA, 201568
Role of gender in juvenile Non-Alcoholic Fatty Liver Disease (NAFLD) pathogenesis
EASL LiverTree™, Veronica MARIN, 201569
Pharmacologic inhibition of hepatic acetyl-CoA carboxylase activity produces improvements multiple dimensions of NASH pathogenesis in non-clinical models
EASL LiverTree™, William ESLER, 201570
Liver histology for biomarker and target discovery
EASL LiverTree™, Peter Schirmacher, 201624
Alcohol and nutrition in NAFLD progression to cancer
EASL LiverTree™, Claus Hellerbrand, 201623
Circulating tumor (stem) cells and liquid biopsy
EASL LiverTree™, Mathias Heikenwälder, 201622
MicroRNA (& lncRNA?) as biomarker and target
EASL LiverTree™, Cecilia MP Rodrigues, 201621
Academic overview: NASH as fertile soil for HCC, including challenge of pre-cirrhotic HCC
EASL LiverTree™, Jean-Francois Dufour, 201620
Impact of alive probiotics supplementation with absorbent smectite gel in NAFLD management: evidence from animals to randomized clinical studies.
EASL LiverTree™, Nazarii Kobyliak, 201617
Probiotic interventions
EASL LiverTree™, Vanessa Stadlbauer, 201616
Microbiota and FXR signaling in NAFLD and obesity, to induce or not to induce - that is the question
EASL LiverTree™, Annika Wahlström, 201615
Academic overview
EASL LiverTree™, Bernd Schnabl, 201614
Mitochondrial dysfunction causes liver steatosis with a different cellular defective phenotype in DHT induced PCOS-like female rodents
EASL LiverTree™, Peng CUI, 201551
Metabolomic Profile Predicts the Onset of Fatty Liver in Young Adults
EASL LiverTree™, Sebastian SOIDINSALO, 201552
Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort
EASL LiverTree™, Philip Newsome, 201554
Expression profiling of 728 miRNAs in a NASH model identifies excellent correlations of hepatic and circulating miR-34a levels with histological lesions in rats and men.
EASL LiverTree™, Rémy Hanf, 201555
Drug repurposing screen to uncover compounds with antifibrotic properties: identification of phase-2 ready candidates that synergize in vitro and in vivo to treat hepatic fibrosis
EASL LiverTree™, Robert Walczak, 201556
Modelling PNPLA3-induced non-alcoholic fatty liver disease using human pluripotent stem cells
EASL LiverTree™, Samantha TILSON, 201557
Features and Outcome of Concomitant Non-alcoholic Liver Disease and Celiac Disease in Adults: A Large Prospective Longitudinal Study
EASL LiverTree™, Sanaa M. Kamal, 201558
Optimal cut-off value to assess changes of intrahepatic fat amount using controlled attenuation parameter in longitudinal setting
EASL LiverTree™, Sang Bong Ahn, 201559
EFFECTIVENESS OF A MULTIDISCIPLINARY TEAM IN NAFLD PATIENTS MANAGEMENT
EASL LiverTree™, Sara POLICARPO, 201560
ASBT inhibitors
EASL LiverTree™, Hanns-Ulrich Marschall, 201611
FGF-19 (FXR downstream target)
EASL LiverTree™, Matias A Avila, 201610
FXR - non- steroidal agonists
EASL LiverTree™, Nikolai V. Naoumov, 201609
FXR - steroidal agonists
EASL LiverTree™, Luciano Adorini, 201608
Bile acids as prognostic signature in NASH
EASL LiverTree™, Marco Arrese, 201607
Academic overview
EASL LiverTree™, Michael Trauner, 201606
NONALCOHOLIC FATTY LIVER DISEASE: EFFECTS OF HUMAN RESISTIN ON IMMUNOLOGICAL CELLS
EASL LiverTree™, Javier Benavides, 201541
Assessment of non invasive markers of fibrosis against collagen quantitation and NASH-CRN scoring in liver biopsies of NAFLD patients
EASL LiverTree™, Roberta Forlano, 201542
Unbiased selection of NAFLD animal model using hepatic whole-genome transcriptomic meta-analysis
EASL LiverTree™, Nicolas Goossens, 201544
Efficacy of the obesity treatment with a probiotic, special diet and metabolic conditioning complex (MetCon).
EASL LiverTree™, OLENA BAKA, 201545
Parameters of liver and pancreas stiffness in children with nonalcoholic liver disease
EASL LiverTree™, olha lukianenko, 201546
CCR2+ INFILTRATING MONOCYTES PROMOTE EXPERIMENTAL STEATOHEPATITIS - THERAPEUTIC IMPLICATIONS OF INHIBITING CCR2
EASL LiverTree™, Oliver Krenkel, 201547
Hepatic stiffness evaluation with shear wave elastography (SWE) in severe obese patients.
EASL LiverTree™, Paola Bizzotto, 201548
Comorbidity specific augmented hepatic injury in a murine model of obesity-induced NAFLD and peritoneal sepsis
EASL LiverTree™, Paul Horn, 201549
miR-21 ABLATION PREVENTS NASH-ASSOCIATED HEPATOCELLULAR CARCINOMA
EASL LiverTree™, Pedro Rodrigues, 201550
Evaluation of the applicability of non-invasive fibrosis scores in a prospective cohort of non-alcoholic fatty liver disease (NAFLD) patients with liver biopsy
EASL LiverTree™, Javier Benavides, 201532
A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Roberta Forlano, 201533
A novel 3D liver microtissue model for studying steatosis in vitro
EASL LiverTree™, Simon Messner, 201534
The combination of Berberis Aristata, Elaeis Guineensis and Coffea Canephora extracts improves insulin resistance in an animal model of NAFLD induced by high fat diet
EASL LiverTree™, Vincenzo Lembo, 201535
Is non-obese fatty liver disease characterized with the same to typical NAFLD features or can be recognized as distinctive condition?
EASL LiverTree™, Natalia Bosak, 201537
REDUCTION OF WEIGHT AND LEVELS OF NONINVASIVE BIOMARKER OF LIVER APOPTOSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE BY LIFESTYLE MODIFICATION PROGRAM DURING 6 MONTHS

EASL LiverTree™, OLENA BAKA, 201538
FREQUENCY OF NON ALCOHOLIC FATTY LIVER DIASEASE IN PATIENTS WITH DIABETES MELLITUS
EASL LiverTree™, Nauman Arif Jadoon, 201539
ATTENUATION COEFFICIENT MEASUREMENT (ACM) AS NOVEL REAL TIME ULTRASOUND ALTERNATIVE TO CAP (FIBROSCAN)
EASL LiverTree™, Nazarii Kobyliak, 201540
LOW TLR9 EXPRESSION IN ADAPTIVE CELLS PROTECTS AGAINST PROGRESSION OF NONALCOHOLIC FATTY LIVER DISEASES
EASL LiverTree™, Javier Benavides, 201522
Q Liver: a novel automated system for assessment of liver steatosis and fibrosis in routine histological images from patients with NAFLD
EASL LiverTree™, Roberta Forlano, 201523
Possibilities of non-invasive assessment of the formation and progression of liver fibrosis in patients with non-alcoholic fatty disease.
EASL LiverTree™, Saidrakhim Lukmonov, 201524
Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
EASL LiverTree™, Simon Messner, 201525
The role of decaffeinated coffee on gut permeability and lipid metabolism in a diet induced animal model of NAFLD
EASL LiverTree™, Vincenzo Lembo, 201526
Probiotics and nutraceuticals: are they one team players in NAFLD prevention
EASL LiverTree™, Natalia Bosak, 201528
The Severity of Nonalcoholic Fatty Liver Disease associated with Insulin resistance and Metabolic syndrome
EASL LiverTree™, Hojung Jung, 201529
Discovery and validation of new modulators of necroptosis using phenotypic high throughput screening of large compound library
EASL LiverTree™, Hugo Brito, 201530